已发表论文

血清白蛋白 - 球蛋白比值对早期非小细胞肺癌的预后价值:一项回顾性研究

 

Authors Wang Y, Li S, Hu X, Wang Y, Wu Y, Li P, Che G

Received 18 October 2018

Accepted for publication 6 March 2019

Published 24 April 2019 Volume 2019:11 Pages 3545—3554

DOI https://doi.org/10.2147/CMAR.S191288

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Justinn Cochran

Peer reviewer comments 2

Editor who approved publication: Dr Ahmet Emre Eskazan

Background: Previous studies demonstrated a significant association between the albumin–globulin ratio (AGR) and various types of cancers. The aim of this study was to evaluate the prognostic value of preoperative AGR in patients with early-stage non-small cell lung cancer (NSCLC).
Methods: Patients diagnosed as NSCLC in a single center between January 1, 2014 and February 29, 2016 were retrospectively reviewed. AGR was defined as the ratio between the serum albumin level and the serum globulin level. Receiver operating characteristics analysis was performed to determine optimal cutoff values. Overall survival (OS) and disease-free survival (DFS) were clinical outcomes of our study. Univariate and multivariate Cox regression analyses were used to identify independent prognostic factors, and the Kaplan–Meier method was used to estimate survival curves.
Results: A total of 279 early stage NSCLC patients were enrolled in our study with the median follow-up of 39 months (range 1–56 months). The statistical analyses manifested that the age (hazard ratio (HR)=1.045, 95% confidence interval (95% CI): 1.010–1.081, =0.011) and AGR =0.002) were independent prognostic factors for OS; larger tumor (HR=1.211, 95% CI: 1.011–1.450, =0.038) and AGR =0.036) were significantly associated with decreased DFS.
Conclusion: The current research reported that the preoperative AGR was an independent prognostic factor for both OS and DFS in early NSCLC, and patients with AGR <1.51 were more likely to have a poor prognosis.
Keywords: albumin-globulin ratio, early non-small cell lung cancer, overall survival; disease-free survival




Figure 2 (A) ROC curve of the AGR for predicting OS. (B) ROC curve of the AGR for predicting DFS.